Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RID is an over-the-counter (OTC) topical treatment for lice infestation (pediculosis), currently developed and marketed by Oystershell (following its acquisition of the brand from Prestige Consumer Healthcare in 2021). The primary formulation is a synergized pyrethrin shampoo or gel. It contains two main active ingredients: pyrethrins, which are natural insecticides derived from chrysanthemum flowers, and piperonyl butoxide, a synergist. The pyrethrins act as neurotoxins by targeting the voltage-gated sodium channels in the nervous system of lice, leading to prolonged channel opening, hyperexcitation, paralysis, and death. Piperonyl butoxide enhances this effect by inhibiting the cytochrome P450 enzymes (microsomal monooxygenases) within the lice that would otherwise detoxify the pyrethrins. It is indicated for the treatment of head lice, pubic (crab) lice, and body lice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pyrethrins + piperonyl butoxide.